香港股市 已收市
基於你的私隱偏好設定,無法提供此內容。在此更新你的設定以查看內容。
  • PR Newswire

    Comanche Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for CBP-4888, an siRNA Investigational Therapy for the Treatment of Preeclampsia

    Comanche Biopharma Corp., a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for Comanche's novel, siRNA therapy to treat preeclampsia. Preeclampsia is a prevalent hypertensive disorder of pregnancy for which there is no existing therapy that can modify disease progression.

  • PR Newswire

    Bruynzeel acquires American museum storage leader Delta

    European market leader in mobile storage systems Bruynzeel Storage Systems acquires Delta Designs Ltd from Kansas (US). Delta Designs is leader in North America for museum and institutions collection storage and is renowned for its high quality custom made museum cabinets. This acquisition, in one of its core segments, helps expanding Bruynzeel's global leadership and accelerates the overall growth strategy to exceed €100 million turnover before 2026. The North American market is the largest in

  • GlobeNewswire

    Global Self-amplifying RNA (saRNA or Replicons) Vaccines Patent Research Report 2023

    Dublin, March 30, 2023 (GLOBE NEWSWIRE) -- The "Self-amplifying RNA vaccines Patent Landscape Analysis 2023" report has been added to ResearchAndMarkets.com's offering. The pandemic has led to research effort and global coordination, resulting in the rapid development of mRNA vaccines and human clinical trials. Currently, there are 2 main types of mRNA vaccines: conventional non-amplifying mRNA and self-amplifying mRNA (saRNA or replicons). saRNAs are larger than non-amplifying mRNAs and maintai